XML 148 R65.htm IDEA: XBRL DOCUMENT v3.20.4
Equity-based participation plans for associates (Tables)
 12 Months Ended
Dec. 31, 2020
Statement [line items]  
Expense related to all equity-based participation and liabilities arising from equity-based payment transactions
(USD millions)
2020
2019
2018
Expense related to equity-based

participation plans


958


1 067


918
Liabilities arising from equity-based payment transactions
269
326
273
Schedule of unvested restricted stock units roll forward
2020
2019


Number

of shares

in millions
Weighted

average fair

value at grant

date in USD


Fair value at

grant date in

USD millions


Number

of shares

in millions
Weighted

average fair

value at grant

date in USD


Fair value at

grant date in

USD millions
Non-vested shares at January 1
25.8
71.1
1 835
25.7
77.1
1 981
Granted
– Annual Incentive
1.1
93.7
103
1.1
78.4
86
– Share savings plans
4.2
95.0
399
4.2
83.0
349
– Select North America
3.3
86.7
286
5.3
64.0
339
– Select outside North America
2.0
89.4
179
2.6
67.4
175
– Long-Term Performance Plan
2.5
85.1
213
2.5
68.9
172
– Long-Term Relative Performance Plan  1
0.2
0.0
0
0.1
0.0
0
– Other share awards
1.5
78.0
117
1.9
67.7
129
Vested
– 13.8
74.2
– 1 024
– 13.3
80.3
– 1 068
Forfeited
– 2.0
75.3
– 151
– 4.3
76.3
– 328
Non-vested shares at December 31
24.8
78.9
1 957
25.8
71.1
1 835
 1  LTRPP grants in 2020 represent incremental payouts based on performance criteria under the plan. In 2019 the LTRPP grants are keep whole awards granted due to the spin-off of the Alcon business.
At April 8, 2019, the Alcon spin-off date, all RSU and PSU holders, who were not entitled to the dividend in kind in the form of Alcon shares received keep whole awards in Novartis shares to compensate for the loss of the Alcon value from their Novartis shares. These keep whole awards were accounted for as a modification. As they did not increase the value of the original grant, they did not lead to additional expense. In the table above, this is reflected by a zero fair value at grant date amount.
Select outside North America  
Statement [line items]  
Disclosure of number and weighted average remaining contractual life of outstanding share options
2020
2019






Options

(millions)
Weighted

average

exercise

price

(USD)






Options

(millions)
Weighted

average

exercise

price

(USD)
Options outstanding

at January 1


3.4


60.9


5.6


59.9
Sold or exercised
– 0.8
57.3
– 2.2
58.4
Outstanding at December 31
2.6
62.0
3.4
60.9
Exercisable at December 31
2.6
62.0
3.4
60.9
Disclosure of range of exercise prices of outstanding share options


Options outstanding












Total/

weighted

average
Number outstanding (millions)
0.4
0.8
1.4
2.6
Remaining contractual life (years)
0.0
1.0
2.0
1.4
Exercise price (USD)
57.0
57.6
66.0
62.0
Select North America  
Statement [line items]  
Disclosure of number and weighted average remaining contractual life of outstanding share options
2020
2019




ADR

options

(millions)
Weighted

average

exercise

price

(USD)




ADR

options

(millions)
Weighted

average

exercise

price

(USD)
Options outstanding

at January 1


9.6


61.9


15.2


60.7
Sold or exercised
– 2.9
59.6
– 5.6
58.6
Outstanding at December 31
6.7
62.9
9.6
61.9
Exercisable at December 31
6.7
62.9
9.6
61.9
Disclosure of range of exercise prices of outstanding share options


ADR options outstanding












Total/

weighted

average
Number outstanding (millions)
0.4
2.3
4.0
6.7
Remaining contractual life (years)
0.0
1.0
2.0
1.5
Exercise price (USD)
57.0
58.3
66.1
62.9